What amount sold does Phoreus Biotechnology, Inc. report in Form D filings?

The latest linked filings report $5.4M sold across 3 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Phoreus Biotechnology, Inc.'s most recent SEC filing?

Phoreus Biotechnology, Inc.'s most recent Form D filing was on 2026-03-13.

How many investors does Phoreus Biotechnology, Inc. have?

The most recent Form D filing lists 3 investor(s).

What type of securities does Phoreus Biotechnology, Inc. offer?

Phoreus Biotechnology, Inc.'s SEC Form D filings indicate equity offerings.

Phoreus Biotechnology, Inc.

CIK: 0001748964·Biotechnology·OLATHE, KS·Corporation

Reported Sold

$5,405,323

Total Filings

Identified Offerings

Last Filed

Mar 13, 2026

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Mar 13, 2026Form D/A — Amendment

Reported sold: $4,434,630 · Target: Indefinite

Rule 506(b)·49 investors

Changed: Reported amount sold, Offering target, Reported investors

Mar 13, 2026Form D — New notice

Reported sold: $420,693 · Target: Indefinite

Rule 506(b)·3 investors

May 11, 2022Form D/A — Amendment

Reported sold: $1,929,392 · Target: $3,000,000

Rule 506(b)·23 investors

Changed: Reported amount sold, Offering target, Reported investors

May 26, 2020Form D — New notice

Reported sold: $0 · Target: $2,000,000

Rule 506(b)·0 investors

Dec 30, 2019Form D/A — Amendment

Reported sold: $550,000 · Target: $1,100,000

Rule 506(b)·7 investors

Changed: Reported amount sold, Offering target, Reported investors, Reported revenue range

Jul 19, 2019Form D/A — Amendment

Reported sold: $300,000 · Target: $1,100,000

Rule 506(b)·4 investors

Changed: Reported amount sold, Offering target, Reported investors, Reported revenue range

Aug 2, 2018Form D — New notice

Reported sold: $50,000 · Target: $1,000,000

Rule 506(b)·1 investor

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

$1 - $1,000,000

Reported commissions across identified offerings

Amendment Rate

57%

Latest reported sold across 3 identified offerings

$5,405,323

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Randall Tosh

Related Person

Appears on 5 filings

Matthew Tomich

Related Person

Appears on 3 filings

Christopher Brandt

Related Person

Appears on 3 filings

Matthew Tomich

Related Person

Appears on 3 filings

Rajeet Pannu

Related Person

Appears on 3 filings

Scott Nagley

Related Person

Appears on 2 filings

Douglas` Shane

Related Person

Appears on 2 filings

Steve Schram

Related Person

Appears on 2 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Mar 13, 2026	New	Indefinite	$420,693	3
Mar 13, 2026	Amendment	Indefinite	$4,434,630	49
May 11, 2022	Amendment	$3,000,000	$1,929,392	23
May 26, 2020	New	$2,000,000	$0	0
Dec 30, 2019	Amendment	$1,100,000	$550,000	7
Jul 19, 2019	Amendment	$1,100,000	$300,000	4
Aug 2, 2018	New	$1,000,000	$50,000	1

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Amplifi Vascular, Inc.

Biotechnology

Offering target: $12,000,000

Filed Jun 30, 2026